Chardan Capital Forecasts Zura Bio FY2025 Earnings

Zura Bio Limited (NASDAQ:ZURA) – Research analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for shares of Zura Bio in a report released on Wednesday, March 26th. Chardan Capital analyst D. Gataulin expects that the company will post earnings of ($0.77) per share for the year. Chardan Capital has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Zura Bio’s current full-year earnings is ($0.65) per share. Chardan Capital also issued estimates for Zura Bio’s FY2026 earnings at ($0.78) EPS.

A number of other brokerages have also recently issued reports on ZURA. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a report on Wednesday, December 11th. Oppenheimer restated an “outperform” rating and issued a $19.00 price target (down previously from $20.00) on shares of Zura Bio in a report on Wednesday. HC Wainwright reaffirmed a “neutral” rating and set a $5.00 price objective on shares of Zura Bio in a report on Tuesday, December 24th. Finally, Guggenheim reissued a “buy” rating and issued a $15.00 target price on shares of Zura Bio in a report on Wednesday. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $15.00.

Zura Bio Trading Down 6.6 %

Shares of ZURA opened at $1.27 on Friday. Zura Bio has a 52-week low of $1.07 and a 52-week high of $6.35. The company has a 50-day simple moving average of $1.46 and a 200-day simple moving average of $2.73.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings data on Tuesday, March 25th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.09. The business had revenue of $0.00 million during the quarter.

Hedge Funds Weigh In On Zura Bio

Several hedge funds have recently bought and sold shares of ZURA. JPMorgan Chase & Co. boosted its stake in shares of Zura Bio by 12,060.8% during the fourth quarter. JPMorgan Chase & Co. now owns 2,633,185 shares of the company’s stock valued at $6,583,000 after acquiring an additional 2,611,532 shares during the last quarter. Braidwell LP purchased a new position in Zura Bio in the 3rd quarter valued at about $10,040,000. Geode Capital Management LLC boosted its stake in shares of Zura Bio by 4.7% during the 4th quarter. Geode Capital Management LLC now owns 955,426 shares of the company’s stock worth $2,389,000 after purchasing an additional 42,801 shares during the last quarter. Sphera Funds Management LTD. purchased a new stake in shares of Zura Bio during the third quarter worth about $2,999,000. Finally, Millennium Management LLC raised its position in shares of Zura Bio by 1,499.0% in the fourth quarter. Millennium Management LLC now owns 701,278 shares of the company’s stock valued at $1,753,000 after buying an additional 657,420 shares during the last quarter. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.